<DOC>
	<DOCNO>NCT01925612</DOCNO>
	<brief_summary>This study 3 part . The purpose Part 1 study ass safety efficacy brentuximab vedotin combination RCHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) ( know BV+RCHOP ) patient DLBCL never treat . Patients randomly assign 1:1 ratio receive RCHOP together 1 2 dos brentuximab vedotin . Patients test see difference side effect 2 group . The purpose Part 2 study ass safety efficacy brentuximab vedotin combination RCHP ( rituximab , cyclophosphamide , doxorubicin , prednisone ) ( know BV+RCHP ) patient CD30-positive DLBCL never treat . Patients enrol receive RCHP together 1.8mg/kg brentuximab vedotin . The purpose Part 3 study ass safety efficacy BV+RCHP compare standard RCHOP patient CD30-positive DLBCL never treat . Patients randomly assign 1:1 ratio receive either BV+RCHP RCHOP . Patients test see difference side effect 2 group .</brief_summary>
	<brief_title>Study Brentuximab Vedotin Combined With RCHOP RCHP Front-line Treatment Patients With Diffuse Large B-cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>In first part study , patient 2 group test see difference response treatment whether difference side effect ( unwanted effect ) . After sponsor study doctor review side effect dose level , notice patient higher dose brentuximab vedotin problem nerve function arm legs ( peripheral neuropathy ) . The patient receive low dose brentuximab vedotin report problem nerve function arm legs ( peripheral neuropathy ) compare patient receive high dose , high dose use anymore combination RCHOP patient treat low dose . The second third part study do see side effect ( unwanted effect ) high dose brentuximab vedotin combine modified version RCHOP omit vincristine , may also cause peripheral neuropathy . The third part study also test see difference BV+RCHP RCHOP response treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Treatmentnaive patient systemic de novo transform diffuse large B cell lymphoma ( DLBCL ) follicular nonHodgkin lymphoma ( NHL ) grade 3b International Prognostic Index ( IPI ) score great equal 3 patient great 60 year age ageadjusted IPI ( aaIPI ) score 2 3 patient less equal 60 year age Stage IAX ( bulk define single lymph node mass &gt; 10 cm diameter ) , IBIV disease Measurable disease least 1.5 cm Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Patients Parts 2 3 must histologically confirm diagnosis CD30positive DLBCL Previous history treat indolent lymphoma History another primary malignancy remission 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma , B-cell</keyword>
	<keyword>Lymphoma , Large B-cell , Diffuse</keyword>
	<keyword>Monomethyl auristatin E</keyword>
</DOC>